Reviewing ERYTECH Pharma S.A. (ERYP)’s and Albireo Pharma Inc. (NASDAQ:ALBO)’s results

Since ERYTECH Pharma S.A. (NASDAQ:ERYP) and Albireo Pharma Inc. (NASDAQ:ALBO) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ERYTECH Pharma S.A. N/A 0.00 N/A -2.79 0.00
Albireo Pharma Inc. 12.17M 25.58 35.30M -3.01 0.00

Demonstrates ERYTECH Pharma S.A. and Albireo Pharma Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 represents ERYTECH Pharma S.A. (NASDAQ:ERYP) and Albireo Pharma Inc. (NASDAQ:ALBO)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
ERYTECH Pharma S.A. 0.00% 0% 0%
Albireo Pharma Inc. -290.06% 0% 0%

Insider & Institutional Ownership

ERYTECH Pharma S.A. and Albireo Pharma Inc. has shares owned by institutional investors as follows: 14.67% and 83%. Competitively, Albireo Pharma Inc. has 0.5% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ERYTECH Pharma S.A. -9.01% -12.13% -34.22% -66.99% 0% -68.76%
Albireo Pharma Inc. -4.16% -8.75% -23.37% -22.26% 1.77% -0.98%

For the past year Albireo Pharma Inc. has weaker performance than ERYTECH Pharma S.A.

Summary

On 4 of the 7 factors Albireo Pharma Inc. beats ERYTECH Pharma S.A.

ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company’s lead product candidate is Eryaspase, which is in various stages of clinical trails for the treatment of pancreatic cancer, ALL, AML, and solid tumors. It is also developing Erymethionase and Eryminase for the treatment of solid tumors; Eryzyme for the treatment of for rare and specialized conditions; and Erymmune for the treatment of TBD. ERYTECH Pharma Société Anonyme has a research agreement with Fox Chase Cancer Center for the preclinical development of erymethionase for the treatment of homocystinuria; a subcontracting agreement for the production of batches of eryaspase for the company's clinical trials; and a subcontracting framework agreement for the optimization of the manufacturing process of the company’s pharma products. ERYTECH Pharma Société Anonyme was founded in 2004 and is based in Lyon, France.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.